Summary
Community-acquired pneumonia (CAP) is a common condition which has a significant mortality. The management of a patient with CAP is centred around assessment and correction of gas exchange and fluid balance together with administration of appropriate antibiotics. Up to 10 different pathogens regularly cause CAP, of which Streptococcus pneumoniae is the most important. These different pathogens cannot be distinguished by clinical features or simple laboratory tests. Microbiological tests are slow and insensitive, so empirical therapy is necessary, at least initially. Accurate assessment of illness severity is the most important factor determining initial management, since this assists the decision of whether to admit the patient to hospital in addition to guiding antibiotic choice and route of administration.
Two different approaches to severity assessment are outlined. Our antibiotic recommendation for empirical therapy for the patient managed at home and the previously fit patient admitted to hospital is amoxicillin. Amoxicillin/clavulanate plus a macrolide is our choice for the severely ill previously fit patient and a third-generation cephalosporin plus a macrolide is recommended for the severely ill patient with comorbidity. Alternative pathogens and specific treatment regimens are also described. There may be several causes of treatment failure, and in patients who fail to respond to therapy, it is essential to review all the initial clinical and laboratory information, which if necessary must be repeated.
Similar content being viewed by others
References
Melbye H, Berdal BP, Straume B, et al. Pneumonia — a clinical or radiographic diagnosis. Scand J Infect Dis 1992; 24: 647–55
Woodhead MA, Macfarlane JT, McCracken JS, et al. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987: I: 671–4
Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in Eastern Finland. Am J Epidemiol 1993; 137: 977–88
Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med 1994; 96: 313–20
Macfarlane JT, Finch RG, Ward MJ, et al. Hospital study of adult community-acquired pneumonia. Lancet 1982; II: 255–8
British Thoracic Society. Community-acquired pneumonia in adults in British hospitals in 1982–1983: a survey of aetiology, mortality, prognostic factors, and outcome. Q J Med 1987; 62: 195–220
Fang G-D, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 1990; 69: 307–16
Mundy LM, Auwaerter PG, Oldach D, et al. Community— acquired pneumonia: impact of immune status. Am J Respir Crit Care Med 1995; 152: 1309–15
Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalisation: 5 year prospective study. Rev Infect Dis 1989; 11: 586–99
Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 1996; 275: 134–41
Almirall J, Morato I, Riera F, et al. Incidence of community acquired pneumonia and Chlamydia pneumoniae infection: a prospective multicentre study. Eur Respir J 1993; 6: 14–8
Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101: 508–15
Berntsson E, Lagergard T, Strannegard O, et al. Etiology of community-acquired pneumonia in outpatients. Eur J Clin Microbiol 1986; 5: 446–7
Ausina V, Coll P, Sambeat M, et al. Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain. Eur J Clin Microbiol Infect Dis 1988;7: 343–7
Berntsson E, Bomberg J, Lagergard T, et al. Etiology of community-acquired pneumonia in patients requiring hospitalisation. Eur J Clin Microbiol 1985; 4: 268–72
Bohte R, van Furth R, van den Broek P J. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995; 50: 543–7
Holmberg H. Aetiology of community-acquired pneumonia in hospital-treated patients. Scand J Infect Dis 1987; 19: 491–501
Levy M, Dromer F, Brion N, et al. Community-acquired pneumonia: importance of initial noninvasive bacteriologic and radiographic investigations. Chest 1988; 92: 43–8
Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51: 179–84
Ortqvist A, Hedlund J, Grillner L, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalisation. Eur Respir J 1990; 3: 1105–13
Steinhoff D, Lode H, Ruckdeschel G, et al. Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin. Clin Infect Dis 1996; 22: 958–64
British Thoracic Society Research Committee and the Puic Health Laboratory Service. The aetiology, management and outcome of severe community-acquired pneumonia in the intensive care unit. Respir Med 1992; 86: 7–13
Moine P, Vercken J-B, Chevret S, et al. Severe community-acquired pneumonia: etiology, epidemiology and prognosis factors. Chest 1994; 105: 1487–95
Ortqvist A, Sterner G, Nilsson JA. Severe community-acquired pneumonia: factors influencing need of intensive care treatment and prognosis. Scand J Infect Dis 1985; 17: 377–86
Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144: 312–8
Woodhead MA, Macfarlane JT, Rodgers FG, et al. Aetiology and outcome of severe community-acquired pneumonia. J Infect 1985; 10: 204–10
Sobradillo V, Ansola P, Baranda F, et al. Q fever pneumonia: a review of 164 community-acquired cases in the Basque country. Eur Respir J 1989; 2: 263–6
Marrie TJ, Haldane EV, Faulkner RS, et al. The importance of Coxiella burnetii as a cause of pneumonia in Nova Scotia. Can J Pu Health 1985; 76: 233–6
Feldman C, Kallenbach JM, Levy H, et al. Community-acquired pneumonia of diverse aetiology: prognostic features in patients admitted to an intensive care unit and a ‘severity of illness’ score. Intensive Care Med 1989; 15: 302–7
Chan CHS, Cohen M, Pang J. A prospective study of community-acquired pneumonia in Hong Kong. Chest 1992; 101: 442–6
Alkhaeyer M, Jenkins PF, Harrison BDW. The outcome of community-acquired pneumonia treated on the intensive care unit. Respir Med 1990; 84: 13–6
Hirani N, Macfarlane JT. Impact of management guidelines on the outcome of severe community-acquired pneumonia. Thorax 1997; 52: 17–21
Sorensen J, Cederholm I, Carlsson C. Pneumonia: a deadly disease despite intensive care treatment. Scand J Infect Dis 1986; 18: 329–35
Pachon J, Prados MD, Capote F, et al. Severe community-acquired pneumonia: etiology, prognosis and treatment. Am Rev Respir Dis 1990; 142: 369–73
Leroy O, Santre C, Beuscart C, et al. A five year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995; 21: 24–31
Torres A, Dorca J, Zalacain R, et al. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicentre study. Am J Respir Crit Care Med 1996; 154: 1456–61
Venkatesan P, Gladman J, Macfarlane JT, et al. A hospital study of community-acquired pneumonia in the elderly. Thorax 1990; 45: 254–8
Bourke SJ, Lightfoot NF. Chlamydia pneumoniae: defining the clinical spectrum of infection requires precise laboratory diagnosis. Thorax 1995; 50 Suppl. 1: S43–8
Levy H. Hantavirus infection. Curr Opin Infect Dis 1997; 10: 103–8
Woodhead MA. Atypical pneumonia. Curr Opin Infect Dis 1997; 10: 101–2
Woodhead MA, Arrowsmith J, Chamberlain-Webber R, et al. The value of routine microbial investigation in community-acquired pneumonia. Respir Med 1991; 85: 313–7
Manresa F, Dorca J. Needle aspiration techniques in the diagnosis of pneumonia. Thorax 1991; 46: 601–3
Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalised for community-acquired pneumonia. Ann Intern Med 1991; 115: 428–36
Karalus NC, Cursons RC, Leng RA, et al. Community-acquired pneumonia: aetiology and prognostic index evaluation. Thorax 1991; 46: 413–8
Neill AM, Martin IR, Weir R, et al. Community-acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51: 1010–6
Fine MJ, Aue TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–50
Mandell LA, Niederman M, The Canadian community-acquired pneumonia consensus conference group. Can J Infect Dis 1993; 4: 25–8
Niederman MD, Low BJ, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418–26
Société de Pathologie Infectieuse de Langue Française. Infections des voies respiratoires: conférence de concensus en thérapeutique anti-infectieuse. Rev Med Infect 1991; 21: 1s–8s
British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 349–50
SEPAR (Spanish Thoracic Society). National recommendations for diagnosis and treatment of community acquired pneumonia. Barcelona: Ediciones Doyma SA, 1992
Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474–80
Drusano G. Pharmacology of anti-infective agents. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. Chap 14. New York: Churchill Livingstone, 1995: 225–33
Johnson AP, Speller DCE, George RC, et al. Prevalence of antibiotic resistance and serotypes in pneumococci in England and Wales: results of observational surveys in 1990 and 1995. BMJ 1996; 312: 1454–6
Committee on Safety of Medicines. Current Proems. Curr Pro Pharmacovig 1996; 21: 6
Woodhead MA, Radvan J, Macfarlane JT. Adult community-acquired staphylococcal pneumonia in the antibiotic era: a review of 61 cases. Q J Med 1987; 64: 783–90
Gialdroni Grassi G, Brumpt I. Sparfloxacin empirical therapy in community-acquired pneumonia: results of a meta-analysis of 2 comparative studies. Drugs 1995; 49 Suppl. 2: 406–8
Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1618–24
Weingarten SR, Riedinger MS, Varis G, et al. Identification of low-risk hospitalised patients with pneumonia: implications for early conversion to oral antimicrobial therapy. Chest 1994; 105: 1109–15
Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalised patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273–6
Macfarlane JT, Miller AC, Smith WHR, et al. Comparative radiographic features of community-acquired legionnaires’ disease, pneumococcal pneumonia, mycoplasma pneumonia and psittacosis. Thorax 1984; 39: 28–33
Holmberg H, Kragsbjerg P. Association of pneumonia and lung cancer: the value of convalescent chest radiography and follow up. Scand J Infect Dis 1993; 25: 93–100
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Finch, R.G., Woodhead, M.A. Practical Considerations and Guidelines for the Management of Community-Acquired Pneumonia. Drugs 55, 31–45 (1998). https://doi.org/10.2165/00003495-199855010-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199855010-00003